Product Name: VemurafenibRequest Vemurafenib
Synonym: PLX4032; PLX 4032; PLX-4032; RG7204; RG-7204; RG 7204; RO5185426; RO 51-85426, RO51-85426, Vemurafenib; Brand name: Zelboraf ,
Vemurafenib Chemical Structure
5 stars, based on 1836 reviewsIUPAC/Chemical name:
Price of Vemurafenib We offer a substantial discount on larger orders,
please inquire via email@example.com
or Fax: 1-201-884-1288 (USA Fax#)
Biological ActivityVemurafenib (also known as PLX4032, RG7204 or RO5185426, marketed as Zelboraf) is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17, 2011. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers. Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17, 2011.
Purchase(buy) Vemurafenib at Active Biochem
and the United State(U.S.), Germany, Japan, France,United Kingdom(UK),Switzerland, Australia distributors.